Back to results
US 2010/0062996 A1Published application
Dioxolane derivates for the treatment of cancer
AssigneeClavis Pharma AS
InventorsFinn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
Life of this patent
Estimating the term…
Abstract
This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
Claims10
A compound having the following formula (I):
- wherein:
- R1 is
- and R3 is selected from the group consisting of hydrogen, methyl, trifluoromethyl, fluorine, chlorine, bromine and iodine;
- and
- X and Y can be either CH or a N atom with at least one of X or Y being N, and
- Z and W are each independently Br, Cl, I, F, OR4 or NHR4 and at least one of Z and W is either OR4 or NHR4, and
- R4 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) where R5 is a C7-23 alkenyl of the general formula
- CH3—(CH2)n-(CH═CH—CH2)m-CH═CH—(CH2)4— (II)
- wherein m is a number from 0 to 2 and n is a number from 0 to 10,
- R2 is H or R5C(O), R5CH2OC(O) or R5CH2NHC(O) where R5 is a C7-23 alkenyl of the general formula
- CH3—(CH2)n-(CH═CH—CH2)m-CH═CH—(CH2)4— (II)
- wherein m is a number from 0 to 2 and n is a number from 0 to 10, with the proviso that R2, R3 and R4 cannot simultaneously be hydrogen, or a
- pharmaceutically acceptable salt thereof.
10 more elements
-9. (canceled)
Dependencies are inferred from the claim text.